Group 1 - The core point of the article is that Tiger Med (03347) has signed a share transfer agreement to sell all issued shares of Shanghai Guanhao Medical Technology Co., Ltd. to Fangda Pharmaceutical Technology (Shanghai) Co., Ltd. for a total consideration of RMB 270 million [1] - The transaction is expected to enhance the operational efficiency of the group by optimizing resource allocation and integrating internal resources [2] - The target group, which primarily engages in clinical trial services, will remain a subsidiary of the company after the sale, allowing for better coordination of business functions within the overall group structure [1][2] Group 2 - The sale is anticipated to promote synergies within the group by simplifying decision-making processes and achieving centralized management [2] - Tiger Med is recognized as a leading provider of comprehensive biopharmaceutical research and development services in China, with a growing global influence [1] - Fangda Group, the buyer, provides research, analysis, and development services throughout the entire product discovery and development process [1]

公告称，出售事项使集团可透过整合内部资源，优化其资源配置并提升营运效率。由于方达集团亦为集 团子公司，出售事项有助于在集团整体架构内更好地协调业务职能及促进协同效应。透过将目标集团业 务整合至方达集团旗下，集团可实现集中管理并简化决策制定程序，从而提升成本效益与营运专注度。 截至本公告日期，方达控股为公司的子公司，其股份于香港联合交易所有限公司上市(股份代号： 3347)。因此，在完成出售事项后，目标公司以及观合医药(香港)有限公司和无锡观合医学检验所有限公 司(均为目标公司的子公司，连同目标公司统称为"目标集团")将仍作为公司的子公司。 公司是中国领先的综合生物制药研发服务提供商，且全球影响力正在不断扩大，主要从事为国内外创新 药和医疗器械企业提供创新药、医疗器械和生物技术相关产品的一站式专业临床研究服务。目标集团主 要从事临床试验服务。方达集团从事提供贯穿整个产品发现及开发过程中的研究、分析及开发服务。 智通财经APP讯，泰格医药(03347)发布公告，于2025年10月10日，公司、公司全资子公司嘉兴欣格医药 科技有限公司(与公司合称"卖方")与方达医药技术(上海)有限公司("买方")(方达控股公司(" ...